Domain Therapeutics

About the deal

Strasbourg, France – Montreal, Canada – May 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, announced today the closing of a US $42m (€39m) series A financing round co-led by Panacea Venture, CTI Life Sciences and 3B Future Health Fund, and joined by adMare BioInnovations, Schroders Capital, Omnes, Turenne Capital, Theodorus, Viva BioInnovator and existing investor Seventure Partners.

This investment is a significant step forward for the French-Canadian company as it seeks to bring novel therapeutic solutions to cancer patients, aimed at bypassing immunosuppression mediated by GPCRs.

Domain Therapeutics will use the proceeds of this financing to i) conduct the clinical development of its EP4R antagonist, DT-9081, ii) advance two additional GPCR programs, including an antiCCR8 antibody, to the Investigational New Drug application stage, and iii) progress its discovery-stage pipeline of a number of first-in-class assets targeting GPCRs, identified through its proprietary platforms.